share_log

Empower Clinics Signs Letter of Intent for $5 Million Equity Capital Facility and Provides Additional Corporate Updates

Empower Clinics Signs Letter of Intent for $5 Million Equity Capital Facility and Provides Additional Corporate Updates

Empower Clinics簽署了500萬美元股權資本融資的意向書,並提供了更多公司最新消息
Accesswire ·  2023/06/06 18:30

VANCOUVER, BC / ACCESSWIRE / June 6, 2023 / EMPOWER CLINICS INC (CSE:EPW) (PINK:EPWCF) ("Empower" or the "Company") an integrated healthcare company with a developing research and clinical trials divisions announces it has entered into a letter of intent with Crescita Capital LLC ("Crescita") for a CAD$5 million equity capital facility.

溫哥華,BC/ACCESSWIRE/2023年6月6日/Empower Clinics Inc(CSE:EPW)(PINK:EPWCF)(“增強能力“或”公司“)一家擁有正在開發的研究和臨床試驗部門的綜合保健公司宣佈,它已經與Cresita Capital LLC(”Cresita“)就500萬加元的股權資本融資簽訂了一份意向書。

Empower has entered into a letter of intent with Crescita for a CAD$5 million equity capital facility that Empower will have three (3) years to utilize to develop the business of the Company.

Empower已經與Cresita簽署了一份意向書,將提供500萬加元的股權資本融資,Empower將有三(3)年的時間來發展公司的業務。

The Letter of Intent (the "Letter of Intent") is intended to describe the present interest of Crescita and Empower to pursue a transaction whereby the Crescita commits to investing CAD$5 million (the "Commitment") in the Company by way of an equity drawdown facility (the "Proposed Transaction"). The terms of the Letter of Intent are not comprehensive and additional terms, including customary representations and warranties, will be incorporated into a definitive equity drawdown facility agreement (the "Definitive Agreement").

意向書(“意向書”)旨在描述Crescita目前的權益,並賦權進行一項交易,藉此Crescita承諾以股權提取安排(“建議交易”)的方式向本公司投資500萬加元(“承諾”)。意向書的條款並不全面,其他條款,包括慣常陳述及保證,將納入最終股權提取融資協定(“最終協定”)。

The Commitment is intended to be used for general working capital purposes, strategic business development and expansion of clinical trial assets. The Commitment allows Empower to drawdown on the facility, at the discretion of the Company's management. The drawdowns are not mandatory, allowing Empower to selectively utilize this financing tool when capital is needed.

這項承諾旨在用於一般營運資本目的、戰略業務發展和擴大臨床試驗資產。這一承諾允許授權在公司管理層酌情決定的情況下縮減設施。提款不是強制性的,允許Empower在需要資本時有選擇地利用這一融資工具。

"We are thrilled with the opportunity to work with the Crescita team who have embraced Empowers path forward to becoming a Site Management Organization (SMO), with the goal of impacting the lives of patients through research and clinical trials." Said Steven McAuley, Empower Chairman & CEO. "Having access to flexible capital as and when the company requires allows us to plan for long term success with a growth strategy based on sustained cash flows."

我們很高興有機會與Cresita團隊合作,他們擁抱了EmPower成為一家網站管理組織(SMO)的道路,目標是通過研究和臨床試驗影響患者的生活。“Empower董事長兼首席執行官史蒂文·麥考利說。能夠在公司需要時獲得靈活的資本,使我們能夠通過基於持續現金流的增長戰略為長期成功制定計劃。“

Mr. McAuley continues, "At the core the Company has always provided patient care, facility management and the administration of our healthcare professionals. These attributes are required to successfully manage sites for clinical trials. We play the all-important role of providing oversight, direction and support to the PI's and their patients ensuring the sites all operate within the guidelines of the study protocol as set by the sponsor and CRO."

McAuley先生繼續說:“公司的核心一直是提供患者護理、設施管理和我們醫療保健專業人員的行政管理。這些屬性是成功管理臨床試驗地點所必需的。我們扮演著向PI及其患者提供監督、指導和支持的重要角色,確保所有地點都在贊助商和CRO制定的研究方案的指導方針下運作。”

The Company also announces that it entered into debt settlement agreements with creditors on May 30th, 2023 for the settlement of debt in the aggregate amount of $68,900 CAD, which was settled through the issuance of an aggregate of 4,593,333 common shares in the capital of the Company (each, a "Share") at a deemed issue price of $0.015 per Share considered (the "Debt Settlement") and on June 1, 2023 the settlement of debt in the amount of $562.25 CAD, which was settled through the issuance of 37,483 Shares at a deemed price of $0.015 per Share.

該公司還宣佈,它於5月30日與債權人簽訂了債務解決協定這是於2023年6月1日清償總額為68,900加元的債務,以發行合共4,593,333股本公司股本中的普通股(每股為“股份”)的方式清償(“債務清償”),並於2023年6月1日清償562.25加元的債務,清償的方式為以每股0.015美元的價格發行37,483股普通股。

All Shares issued pursuant to the debt settlement have been issued with no hold period with prior written consent of the Canadian Securities Exchange. None of the Shares will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

根據債務結算髮行的所有股票均已在事先獲得加拿大證券交易所書面同意的情況下發行,沒有持有期。任何股票都不會根據修訂後的1933年美國證券法進行登記,如果沒有登記或獲得適用的豁免登記要求,任何股份都不能在美國發行或出售。本新聞稿不應構成出售或邀請購買公司任何證券的要約,也不應在任何司法管轄區出售任何此類要約、招攬或出售將是非法的證券。

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions, and engagement with management

本新聞稿可在AGORACOM上的授權診所驗證論壇上獲取,以供股東討論、提問和與管理層接觸

To get enhanced access to investor information about Empower Clinics, please visit the download page to get your Empower Clinics Investor Experience Wallet Pass today.

要獲取有關Empower診所的投資者資訊,請訪問下載頁面,今天即可獲得Empower診所投資者體驗錢包通行證。

ABOUT EMPOWER:

關於授權

Empower is an integrated healthcare company with multi-disciplinary clinics, a Canadian medical device company and has launched its first clinical research site becoming a Site Management Organization (SMO) in Dallas, TX. Empower is a leader in integrated healthcare and research solutions and is reshaping the model for patient-first wellness.

Empower是一家擁有多學科診所的綜合性醫療保健公司,是一家加拿大醫療器械公司,並在德克薩斯州達拉斯推出了其首個臨床研究網站,成為網站管理組織(SMO)。Empower是綜合醫療和研究解決方案領域的領先者,正在重塑患者至上的健康模式。

ON BEHALF OF THE BOARD OF DIRECTORS:

我謹代表董事會:

Steven McAuley
Chief Executive Officer

史蒂文·麥考利
首席執行官

CONTACTS:

聯繫人:

Media:
Steven McAuley CEO s.mcauley@empowerclinics.com
+1 855-855-9058

媒體:
首席執行官Steven McAuley電子郵件:s.mcauley@empower Clinics.com
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
+1 855-855-9058

投資者:
塔瑪拉·梅森
業務發展與溝通
郵箱:t.mason@empower Clinics.com
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

對前瞻性陳述的免責聲明

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: that the Company will impact the lives of patients through research and clinical trials, if at all. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the parties will be able to negotiate and enter into the Definitive Agreement on mutually agreeable terms; that legal and financial due diligence will be completed to the satisfaction of the parties; that all necessary third party approvals will be obtained. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

本新聞稿包含適用於加拿大證券法的某些“前瞻性陳述”或“前瞻性資訊”(統稱為“前瞻性陳述”)。除有關歷史事實的陳述外,所有陳述均為前瞻性陳述,均基於截至本新聞稿發佈之日的預期、估計和預測。前瞻性表述常常可以用“計劃”、“繼續”、“預期”、“專案”、“打算”、“相信”、“預期”、“估計”、“可能”、“將”、“潛在”、“建議”和其他類似詞語,或某些事件或條件“可能”或“將”發生的資訊來識別。本新聞稿中的前瞻性陳述包括以下陳述:公司將通過研究和臨床試驗影響患者的生活(如果有的話)。該等前瞻性表述基於管理層目前已知的假設,受風險和不確定因素的影響,可能會導致實際結果、業績或發展與前瞻性表述中包含的內容大不相同,包括:雙方將能夠以相互同意的條款談判和簽訂最終協定;法律和財務盡職調查的完成程度將令各方滿意;將獲得所有必要的第三方批准。不能保證前瞻性陳述中預期的任何事件將按照預期的條款或時間發生,或者根本不能保證,或者如果發生了,公司將從中獲得什麼好處。告誡讀者不要過度依賴本新聞稿中的前瞻性陳述,這些前瞻性陳述完全受這些警告性陳述的限制。除適用的證券法明確要求外,公司沒有義務更新或修改本新聞稿中的任何前瞻性陳述,除非適用的證券法明確要求,無論是由於新資訊、未來事件還是其他原因。

SOURCE: Empower Clinics Inc.

資料來源:Empower Clinics Inc.


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論